Chronic Bronchitis Market Analysis and Size
The global chronic bronchitis market is expected to grow considerably over the projected period. The global increase in allergic reactions, as well as the growth of emerging markets, are moving this industry ahead. The increased prevalence of asthma and COPD, both of which cause severe coughing, is driving the chronic bronchitis market. The market is growing and is expected to grow fast throughout the projected period.
Pharmanucleus investigates the growth rate of the global chronic bronchitis market from 2023 to 2030. During the projected period, the worldwide chronic bronchitis market is estimated to grow at a CAGR of more than 4.0%. The Pharmanucleus team performed a thorough market analysis that included expert research, patient epidemiology, pipeline analysis, price analysis, and regulatory framework, as well as market data such as market size, growth rate, market segmentation, geographical coverage, market participants, and market situation.
Market Definition
Chronic bronchitis is an inflammatory disease that produces swelling and pain in the airways over time. The symptoms appear gradually and build to severe, maybe irreversible lung damage. A three-month cough happens every two years. The most common causes of chronic bronchitis include smoking and certain kinds of chronic obstructive pulmonary disease (COPD).
Global Acute Bronchitis Market Dynamics
Drivers
- Increasing Prevalence of COPD
The rising incidence of COPD is a significant factor driving market expansion. According to a WHO report from June 2021, chronic obstructive pulmonary disease (COPD) is the third greatest cause of mortality globally, accounting for 3.23 million deaths in 2019. As a result, the rising prevalence of COPD is boosting need for chronic bronchitis therapy.
- Growing Demand for Combination Therapy
Combination treatment is becoming increasingly popular since it is more effective than taking a bronchodilator and a corticosteroid individually. The growing number of patients effectively treated with combination therapy who did not respond to bronchodilators or corticosteroids is predicted to fuel the worldwide chronic obstructive pulmonary disease treatment market.
Opportunities
- Rising Prevalence of Smoking
Smoking is one of the leading causes of death in the United States, resulting in more than 480,000 deaths each year. Smoking was highest among people aged 25-44 and 45-64. Thus, in turn, this leads to chronic bronchitis and creates opportunities for market growth.
- Advanced Clinical Research and Innovative Strategies
Many industry participants are eager to put in place strategic measures that will help the sector thrive. The US Food and Drug Administration authorised Brovana in February 2022 for the treatment of bronchoconstriction in persons with chronic obstructive pulmonary disease (COPD). Brovana contains a bronchodilator, which is a medication that relaxes and widens the airways, hence relieving bronchoconstriction.
Restraints/Challenges
- Lack of Awareness
Lack of patient awareness about the disease and differentiated symptoms could curb the growth of the global acute bronchitis market over a forecast period.
- High Cost
The huge expenditure required for chronic bronchitis treatment is surely hampering the growth of the market.
This Global Chronic Bronchitis Market report provides details about recent new developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share , the impact of national and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic analysis of market growth, market size, category market growth, niches and application dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To obtain more insights on the Global Chronic Bronchitis Market, contact Pharmanucleus for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Chronic Bronchitis Market Scope
The global chronic bronchitis market is classified into four segments: treatment type, drug class, administration technique, end user, and distribution channel. Growth in these sectors will help you analyse weak growth areas in industries and provide users with important market knowledge and industry insights to help them make strategic decisions to uncover major market applications.
Treatment Type
- Pharmacological
- Nonpharmacological
- Others
Drug Class
- Bronchodilators
- Glucocorticoids
- Antibiotic
- Phosphodiesterase-4 Inhibitors
- Others
Route of Administration
- Oral
- Parenteral Inhalational
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospitals
- Specialty Clinics
- Others
Regional Analysis/Insights
The global chronic bronchitis market is analyzed and market size insights and trends are provided by treatment type, drug class, route of administration, end user, and distribution channel as listed above.
The major countries covered in the global Chronic Bronchitis market report are USA, Canada & Mexico North America, Germany, France, UK, Netherlands, Switzerland , Belgium, Russia, Italy, Spain, Turkey, the rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia Pacific (APAC) within Asia Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) within Middle -East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.
North America holds the largest market share owing to increasing infections in the geriatric population and growing smoking population.
Because of the rising incidence of COPD, asthma, and other lung disorders, as well as enhanced government and pharmaceutical organisation efforts to raise awareness, Asia-Pacific is likely to account for the greatest market share in the Chronic Bronchitis market in the next years.
The nation portion of the research also includes individual market affecting elements and changes in legislation in the market that affect present and future market trends. Additionally, the presence and availability of global brands, as well as the issues they face owing to big or scarce competition from local and domestic brands, are taken into account when giving forecast analysis of nation data.
Post COVID Impact
The post-COVID-19 era has brought significant impacts on various sectors, including healthcare. The Chronic Bronchitis Market has experienced notable transformations as a result of the pandemic. Chronic bronchitis is a respiratory condition characterized by persistent coughing, inflammation of the bronchial tubes, and excessive mucus production. Here are the key post-COVID-19 impacts on the Chronic Bronchitis Market:
Increased Awareness: The COVID-19 pandemic has raised public awareness about respiratory health. This has led to a greater understanding of chronic bronchitis and its risk factors, driving more individuals to seek diagnosis and treatment.
Telemedicine Adoption: With the need to maintain social distancing, telemedicine has emerged as a vital tool for healthcare consultations. Patients with chronic bronchitis can now access remote medical services, receive prescriptions, and monitor their condition from the safety and comfort of their homes.
Emphasis on Prevention: COVID-19 has highlighted the importance of preventive measures to safeguard respiratory health. Governments and healthcare organizations are implementing awareness campaigns and policies focused on reducing smoking rates, improving air quality, and promoting vaccination to prevent respiratory infections like bronchitis.
Research and Development: The pandemic has accelerated research efforts in respiratory medicine, leading to advancements in the treatment of chronic bronchitis. New therapies, drugs, and inhalation devices are being developed to enhance patient outcomes and alleviate symptoms.
Market Expansion: The growing recognition of chronic bronchitis has resulted in an expanded market for pharmaceutical companies and medical device manufacturers. This has led to increased investment in research, development, and production of innovative treatments and devices for managing the condition.
Competitive Landscape
The worldwide chronic bronchitis market competitive landscape includes information on each player. Company overview, financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance are all included. The data points presented above are only linked to the firms' emphasis on the worldwide chronic bronchitis market.
Key players operating in the global chronic bronchitis market include:
- Bayer AG (Germany
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sun Pharmaceutical Industries Ltd. (India)
- Hikma Pharmaceutical PLC (U.S.)
- Amneal Pharmaceuticals LLC. (U.K.)
- Aurobindo Pharma (India)
- Johnsons & Johnsons Private limited (U.S.)
GlaxoSmithKline Plc (U.S.)